Delray Beach

Delphine Coles

ENT and Allergy Associates of Florida

Tinnitus

Meniere Disease

Hearing Loss

Vertigo

Dizziness

SPI-1005

OTO-313

Otonomy

Sound Pharmaceuticals

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

ENT and Allergy Associates of Florida | Delray Beach

Site insights

Contact this site

Active trials

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

Trial sponsors